Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 16:01 ET
|
Viridian Therapeutics, Inc
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED...
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
May 08, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Partnership to support one of the Company’s preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2023 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential...
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
May 02, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
April 20, 2023 13:41 ET
|
Viridian Therapeutics, Inc
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial...
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
April 20, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase...
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
April 12, 2023 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing...
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 08, 2023 07:00 ET
|
Viridian Therapeutics, Inc
- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with...
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
March 07, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data...